Featured Research

from universities, journals, and other organizations

Middle East respiratory syndrome coronavirus: MERS-CoV treatment effective in monkeys

Date:
September 8, 2013
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
Scientists report that a combination of two licensed antiviral drugs reduces virus replication and improves clinical outcome in a recently developed monkey model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Their study expands on recent work showing that a combination of ribavirin and interferon-alpha 2b stops MERS-CoV from replicating in cell culture.

Electron microscope image of MIddle East Respiratory Syndrome virus particles, colorized in yellow.
Credit: NIAID

National Institutes of Health (NIH) scientists report that a combination of two licensed antiviral drugs reduces virus replication and improves clinical outcome in a recently developed monkey model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.

Their study, which appears as a letter in the Sept. 8 edition of Nature Medicine, expands on work published in April showing that a combination of ribavirin and interferon-alpha 2b stops MERS-CoV from replicating in cell culture. Both antivirals are routinely used together to treat viral diseases such as hepatitis C.

In the latest study, investigators at NIH's National Institute of Allergy and Infectious Diseases (NIAID) infected six rhesus macaques with MERS-CoV and, eight hours later, treated half of them with the two-drug regimen. Compared to the untreated animals, the treatment group showed no breathing difficulties and only minimal X-ray evidence of pneumonia. The treated animals also had lower amounts of virus and less severe tissue damage in the lungs.

As of Aug. 30, 2013, the World Health Organization has reported 108 human cases of MERS-CoV infection, including 50 deaths. Given the current lack of treatment options, the authors of this study conclude that combined ribavirin and interferon-alpha 2b therapy should be considered as an early intervention.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Journal References:

  1. Darryl Falzarano, Emmie de Wit, Angela L Rasmussen, Friederike Feldmann, Atsushi Okumura, Dana P Scott, Doug Brining, Trenton Bushmaker, Cynthia Martellaro, Laura Baseler, Arndt G Benecke, Michael G Katze, Vincent J Munster, Heinz Feldmann. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques. Nature Medicine, 2013; DOI: 10.1038/nm.3362
  2. Darryl Falzarano, Emmie de Wit, Cynthia Martellaro, Julie Callison, Vincent J. Munster, Heinz Feldmann. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Scientific Reports, 2013; 3 DOI: 10.1038/srep01686
  3. Vincent J. Munster, Emmie de Wit, Heinz Feldmann. Pneumonia from Human Coronavirus in a Macaque Model. New England Journal of Medicine, 2013; 368 (16): 1560 DOI: 10.1056/NEJMc1215691

Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "Middle East respiratory syndrome coronavirus: MERS-CoV treatment effective in monkeys." ScienceDaily. ScienceDaily, 8 September 2013. <www.sciencedaily.com/releases/2013/09/130908135754.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2013, September 8). Middle East respiratory syndrome coronavirus: MERS-CoV treatment effective in monkeys. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2013/09/130908135754.htm
NIH/National Institute of Allergy and Infectious Diseases. "Middle East respiratory syndrome coronavirus: MERS-CoV treatment effective in monkeys." ScienceDaily. www.sciencedaily.com/releases/2013/09/130908135754.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

More Coverage


Two Common Drugs May Help Treat Deadly Middle East Respiratory Syndrome

Sep. 10, 2013 Treatment with two common drugs reduced viral replication and lung damage when given to monkeys infected with the virus that causes Middle East Respiratory Syndrome. The condition is a deadly ... read more
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins